Next, the search for effective target antigens other than CD19 has progressed by targeting the B-cell maturation antigen (BCMA), which is expressed only on plasma cells and myeloma cells of patients with multiple myeloma [183,184,185]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.